Synthesis and Biological Evaluation of Cyclobutane-Based β3 Integrin Antagonists: A Novel Approach to Targeting Integrins for Cancer Therapy

• Published in: Cancers Vol. 15; no. 16; p. 4023
• Main Authors: Sutherland, Mark, Gordon, Andrew, Al-Shammari, Fatemah O. F. O, Throup, Adam, Cilia La Corte, Amy, Philippou, Helen, Shnyder, Steven D, Patterson, Laurence H, Sheldrake, Helen M
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.08.2023; MDPI
• Subjects: Analysis; Angiogenesis; Antimitotic agents; Antineoplastic agents; Antitumor agents; Blood platelets; Cancer; Cancer therapies; Care and treatment; Cell surface; Chromatography; Clinical trials; cyclobutane; Development and progression; Drug delivery; Drug development; drug discovery; Drug dosages; Eptifibatide; Health aspects; integrin αIIbβ3; integrin αvβ3; Integrins; Ligands; Medical prognosis; Melanoma; Metastases; Metastasis; Pharmacokinetics; Physiological aspects; Potassium; RGD mimetic; Tirofiban; Tumors; Canada; United Kingdom; United Kingdom > UK
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15164023

The Arg-Gly-Asp (RGD)-binding family of integrin receptors, and notably the β3 subfamily, are key to multiple physiological processes involved in tissue development, cancer proliferation, and metastatic dissemination. While there is compelling preclinical evidence that both αvβ3 and αIIbβ3 are important anticancer targets, most integrin antagonists developed to target the β3 integrins are highly selective for αvβ3 or αIIbβ3. We report the design, synthesis, and biological evaluation of a new structural class of ligand-mimetic β3 integrin antagonist. These new antagonists combine a high activity against αvβ3 with a moderate affinity for αIIbβ3, providing the first evidence for a new approach to integrin targeting in cancer.